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Aim: Treatment non-adherence is a common problem in patients suffering from schizophrenia and depression. This study investigated 
the possible relationships between symptom severity, quality of sleep, and treatment adherence. Methods: Thirty outpatients with 
schizophrenia and 58 outpatients with depression were enrolled in this study. The beck depression Inventory-II, the positive and negative 
syndrome scale, and the pittsburgh sleep quality index were used to assess symptom severity and quality of sleep, and sleep log data were 
used to measure treatment adherence. Results: The preliminary results showed no significant relationship between symptom severity 
and treatment adherence or between quality of sleep and treatment adherence in patients with depression. However, a significant positive 
relationship was found between negative symptoms and treatment adherence and a significant negative relationship between quality of 
sleep and treatment adherence in patients with schizophrenia. Conclusion: The present exploratory study revealed a positive relationship 
between symptom severity and treatment adherence and a negative relationship between quality of sleep and treatment adherence in 
patients with schizophrenia, but no significant relationships in patients with depression were found. Future studies are needed in order to 
gain a better understanding of possible risk factors related to treatment non-adherence.
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INTRODUCTION
Dropout is a serious problem in treating patients 
because treatment can only be effective if delivered 
adequately and completely.[1] To date, very little is 
known about possible risk factors that might predict 
patient dropout.[2] Findings by Herman et al.[3] indicate 
that early treatment dropout is an essential factor in 
determining treatment success and failure because 
in case of dropout, patients receive little or nothing 
of the intervention involved and, therefore, cannot 
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benefit from therapy. “Adherence to treatment” refers 
to the extent to which a patient’s behavior conforms 
to the advice of health professionals.[4] Although 
dropout and adherence to treatment are related 
issues, there are also important distinctions between 
these two concepts.[5]
Clinical psychologists have reported that, 
unfortunately, non-compliance with homework 
as part of cognitive-behavioral therapy is a 
common phenomenon in clinical practice.[6] This 
is problematic because research has shown that 
homework compliance is positively associated with 
reduced symptom severity.[7]
Treatment non-adherence is a common problem 
in patients suffering from depression or 
schizophrenia.[8] In cases of schizophrenia, poor 
adherence to medication and psychosocial treatment 
are prevalent and increase the probability of relapse 
and re-hospitalization.[9] In their review of 39 studies 
published in English since 1980 and specifically 
examining risk factors for medication non-adherence, 
Lacro et al.[10] pointed out that in those studies, 
the mean rate of non-adherence to medication for 
patients with schizophrenia was 41%. Moreover, in 
their systematic review of 103 studies on adherence 
to treatment by patients with psychosis, Nosé et al.[11] 
reported a mean rate of failure to keep scheduled 
follow-up appointments of 24% in patients with 
psychoses. Rates of treatment dropout are reported 
less often; the figures for this range from 20% to 
56% in patients with schizophrenia.[12-14] In patients 
with depression, the severity of the disorder has 
been associated with treatment dropout in some 
studies,[15] but not in all.[16] Agreeing with Last et al.[15] 
Leserman[17] indicated that patients with depression 
were less likely to adhere to a treatment program 
than patients without depression and experienced 
worse outcomes in health.
Schizophrenia and depression are both seemingly 
dropout-prone disorders,[18,19] but which specific factors 
can be related to the non-adherence to treatment 
in patients with either condition is arguable. An 
association between less severe psychiatric symptoms 
and better treatment adherence was found,[20] and both 
the severity of the disease and the patient’s attitude 
towards the prescribed medication were found to be 
related to adherence in patients with schizophrenia.[21] 
In this case, the severity was found to correlate 
negatively with treatment adherence while the patient’s 
attitude towards the prescribed medication was found 
to correlate positively with treatment adherence.
Also, a role for quality of sleep in treatment adherence 
of patients with schizophrenia or depression has 
been suggested.[22,23] Phillips and colleagues,[23] for 
instance, considered adherence to treatment to be 
a factor that correlated with sleep disturbance and 
depression. Their results showed that women with 
greater sleep disturbances also had a higher level of 
depressive symptoms and poor adherence to their 
medication regimen. According to these findings,[23] 
not only the severity of the disorder but also suffering 
from sleep disturbances might be related to treatment 
non-adherence in patients with schizophrenia or 
depression. A possible role for quality of sleep in 
treatment adherence is further supported by the fact 
that both schizophrenia and depression are co-morbid 
with sleep disturbances.[24,25]
However, to date, not much research has been conducted 
on the specific factors that can be related to the non-
adherence to treatment in patients with schizophrenia 
or depression. As a result, more research is needed 
on the possible factors suggested in the literature, 
symptom severity and quality of sleep, as being 
related to treatment non-adherence. The aim of the 
present study was, therefore, to investigate the possible 
relationships between symptom severities, quality of 
sleep, and treatment adherence further. Thereby, noting 
that treatment non-adherence limits the improvements 
in independent living, employment, and quality of life 
to a large degree in patients with schizophrenia or 
depression is important.[26] First, patients with a more 
severe depression were hypothesized to have worse 
treatment adherence than patients with a less severe 
depression. Secondly, patients with schizophrenia 
who show more positive and negative symptoms were 
hypothesized to have worse treatment adherence than 
patients with schizophrenia who show fewer positive 
and negative symptoms. A final hypothesis was that 
patients who have a poor quality of sleep have worse 
treatment adherence than patients who have a good 
quality of sleep.
METHODS
Setting and participants
The participants in this study consisted of 17 female 
and 13 male adult patients with schizophrenia with 
an average age of 41 (SD = 8.80) and 40 females 
and 18 males adult patients with depression with 
an average age of 45 (SD = 12.14). All participants 
were outpatients of the LVR-Klinik Bedburg-Hau in 
Germany and were diagnosed by their psychiatrist 
according to the 10th revision of the International 
Classification of Diseases and Related Health Problems 
(ICD-10).[27] Note that in Germany, the ICD-10[27] is 
used instead of the Diagnostic and Statistical Manual 
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of Mental Disorders, fifth edition (DSM-V).[28] The 
inclusion criterion for all participants was that 
they be between 18 and 65 years of age, and the 
exclusion criteria for the patients with schizophrenia 
or depression were substance abuse, epilepsy, and 
other neurological disorders. Finally, all patients 
took part voluntarily without any inducement and 
signed the informed consent form.
Material
BDI-II
The Beck Depression Inventory-II (BDI-II)[29] was 
used to assess depression severity. The BDI-II is 
a 21-item self-report inventory, and each item is 
rated on a 4-point scale (i.e. from 0 to 3). Thus, an 
individual’s scoring range would lie between 0 and 
63. The higher the total scores on the BDI-II, the more 
severe the depressive symptoms of the patients are.
PANSS
In addition, the Positive and Negative Syndrome Scale 
(PANSS)[30] was used to measure the symptom severity 
of the patients with schizophrenia. The PANSS has 
to be filled in by a psychiatrist. It consists of three 
subscales: the positive scale, the negative scale and 
the general psychopathology scale. The scoring range 
for an individual is between 7 and 49 for the positive 
scale, 7 and 49 for the negative scale, and 16 and 112 
for the general psychopathology scale; as a result, the 
total scores on the PANSS are between 30 and 210. 
The higher the total scores on the PANSS are, the 
more severe the positive and negative symptoms of 
the individuals with schizophrenia are.
PSQI
The Pittsburgh Sleep Quality Index (PSQI)[31] was 
used to measure the subjective quality of sleep of the 
patients with schizophrenia or depression. The PSQI 
is a self-report inventory and measures sleep quality 
and patterns of sleep. It has seven separate domains: (1) 
“subjective sleep quality”; (2) “sleep latency”; (3) “sleep 
duration”; (4) “habitual sleep efficiency”; (5) “sleep 
disturbances”; (6) “use of sleep medication”; and (7) 
“daytime dysfunction over the last month”. Individuals 
score all items on a Likert scale, ranging from 0 to 3. As 
a result, the total scores on the PSQI are between 0 and 
21, and the higher the total PSQI score is, the poorer 
the quality of sleep is. In daily clinical practice, often 
a cut-off score of 5[31] is used, meaning that participants 
who score below 5 have a good quality of sleep and 
participants who score above 5 have a poor quality of 
sleep. In the present study, the total PSQI scores were 
used for further analyses.
Sleep log
As part of the treatment adherence measurements 
for the schizophrenic and depressive patients,[32] the 
participants were asked to complete a sleep log for two 
weeks. It consisted of the following six sleep variables: (1) 
“total sleep time”；(2) “how many minutes awake during 
the night”；(3) “how many minutes awake before falling 
asleep”; (4) “how relaxing was your sleep”; (5) “did you 
feel exhausted”; (6) “how was your average performance 
level today”. The sleep log was to be completed every 
morning just after awakening and every evening just 
before falling asleep.[33] Completing the sleep log took 
approximately 10 min a day, 140 min in total.
Procedure
Every participant in the group of patients with 
depression was asked to complete the BDI-II 
and the PSQI. The PANSS was completed by the 
patient’s psychiatrist in the group of patients with 
schizophrenia, and these patients were also asked 
to complete the PSQI. All participants were asked 
to keep a sleep log and return it to their clinical 
psychologist at the end of the two weeks. At the end of 
the study, a debriefing was offered to all participants, 
in which they were individually informed of their 
test results. The study was approved by the local 
ethics committee (Ärztekammer Nordrhein, number: 
2008331); moreover, the clinical trial has officially 
been registered under number NTR3132 at the Dutch 
Trial Register (see also http://www.trialregister.nl/
trialreg/admin/rctview.asp? TC = 3132). Finally, 
the study was performed in accordance with the 
Declaration of Helsinki (http://www.wma.net/
en/30publications/10policies/b3/).
Design and statistics
An experimental design was used in which the first 
categorical dependent variable was called “Absolute 
Treatment Adherence”; it was measured by using 
the returned sleep logs (i.e. if the patient returned 
the sleep log, the patient was considered as being 
treatment adherent vs. if the patient did not return 
the sleep log, the patient was considered as not 
being treatment adherent). The second continuous 
dependent variable was called “Degree of Treatment 
Adherence” because it consisted of the total number 
of days the participants had completed the sleep log, 
with 0 day meaning a very low degree of treatment 
adherence and 14 days meaning a very high degree 
of treatment adherence. In other words, “Absolute 
Treatment Adherence” showed whether a patient 
returned the sleep log or not while “Degree of 
Treatment Adherence” showed to what degree the 
patient was treatment adherent. Note that in the 
present study, a very narrow definition of the word 
“treatment” was used (e.g. completing and returning 
a sleep log) and did not include any pharmacological 
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Table 2: The number of adherent and non-adherent 
patients with schizophrenia and their mean scores and 
standard deviations on the PANSS and the PSQI
Adherence Instrument Number Mean SD
Non-adherent PANSS-total
PANSS-negative
PANSS-positive
PANSS-psychopathology
PSQI
16
16
16
16
16
67.81
16.81*
14.13
36.88
6.31
19.56
6.76
7.37
11.62
3.32
Adherent PANSS-total
PANSS-negative
PANSS-positive
PANSS-psychopathology
PSQI
14
14
14
14
14
81.86
23.43*
20.71
44.86
8.57
26.74
10.42
26.44
14.36
4.50
Total PANSS-total
PANSS-negative
PANSS-positive
PANSS-psychopathology
PSQI
30
30
30
30
30
74.37
19.90*
17.20
40.60
7.37
23.86
9.14
18.78
13.37
4.01
*P < 0.05; PANSS: positive and negative syndrome scale
Table 1: The number of adherent and non-adherent 
patients with depression and their mean scores and 
standard devitations on the BDI-II and the PSQII
Adherence Instrument Number Mean SD
Non-adherent BDI-II
PSQI
21
21
20.81
9.05
12.21
 4.28
Adherent BDI-II
PSQI
37
37
19.24
9.51
11.28
4.17
Total BDI-II
PSQI
58
58
19.81
9.34
11.54
4.18
All P > 0.05; PSQI: pittsburgh sleep quality index; BDI-II: beck depression 
inventory-II
Table 3: Results of the multiple regression analysis for 
variables predicting degree of treatment adherence
Predictor B SEB β
Constant 8.95 2.48 -
BDI-II -0.03 0.07 -0.05
PSQI 0.13 0.21 0.08
R² = 0.01; B: unstandardized multiple regression coefficient; SEB: standard 
error of multiple regression coefficient; β: standardized multiple regression 
coefficient
Table 4: Results of the multiple regression analysis for 
variables predicting degree of treatment adherence
Predictor B SEB β
Constant -2.14 4.13 -
PANSS-positive 0.08 0.07 0.21
PANSS-negative 0.21 0.25 0 .29
PANSS-psychopathology 0.01 0.32 0.02
PANSS-total -0.02 0.22 -0.06
PSQI 0.65 0.31 0.39*
R² = 0.27 *P < 0.05; B: unstandardized multiple regression coefficient; SEB: 
standard error of multiple regression coefficient; β: standardized multiple 
regression coefficient
interventions; neither did we use the sleep variables 
recorded in the sleep log to predict adherence. The 
scores on the BDI-II, the PANSS, and the PSQI served 
as “predictor” variables.
With SPSS version 22.0[34] a discriminant function 
analysis[35] was conducted with “Absolute Treatment 
Adherence” as a categorical dependent variable 
and the scores on the BDI-II and PSQI as predictor 
variables for the group of patients with depression. 
For the group of patients with schizophrenia, a 
discriminant function analysis was performed with 
“Absolute Treatment Adherence” as a categorical 
dependent variable and the scores on the PANSS 
and PSQI as predictor variables. Furthermore, two 
multiple regression analyses[36] were conducted 
with one analysis containing “Degree of Treatment 
Adherence” as the dependent variable and the score 
on the BDI-II, as well as the score on the PSQI, as 
independent variables for the group of patients 
with depression. In the second analysis, “Degree of 
Treatment Adherence” was used as the dependent 
variable, and the score on the PANSS, as well as the 
score on the PSQI, were used as independent variables 
for the group of patients with schizophrenia.
RESULTS
Absolute treatment adherence in the depression group
For the group of patients with depression, a 
discriminant function analysis was conducted 
in order to identify patients who were adherent to 
treatment vs. those who were not; this was done 
using the patient’s scores on the BDI-II and the PSQI 
as predictors. The discriminant function analysis 
explained 100% of the variance, canonical R² = 0.01 
(Note that this does not mean that the discriminant 
function accounts for 100% of the variance in the 
response variable; rather, this means that it is the only 
discriminant function extracted for the analysis).[37] 
The discriminant function analysis did not 
significantly differentiate the patients who were 
treatment-adherent from the ones who were 
not [Λ = 0.99, χ² (2) = 0.43, P > 0.05]. Table 1 
summarizes the descriptive statistics of the 
group of patients with depression.
Absolute treatment adherence in the schizophrenia 
group
In addition, a discriminant function analysis was 
conducted for the group of patients with schizophrenia. 
The discriminant model was used to identify patients 
who were adherent to treatment versus those who were 
not treatment-adherent by using the patient’s scores on 
the PANSS (also divided into positive symptoms, negative 
symptoms, and general psychopathology) and on the 
PSQI as predictors. The discriminant function analysis 
explained 100% of the variance, canonical R² = 0.26. The 
discriminant function analysis did not significantly 
differentiate the patients who were treatment-
adherent from the ones who were not [Λ = 0.74, 
χ² (5) = 7.67, P > 0.05]. The correlations between 
outcomes and the discriminant function revealed 
that the score on the PANSS-negative loaded 
highly onto the function (r = 0.67), followed by the 
score on the PSQI (r = 0.50). Table 2 summarizes 
the descriptive statistics of the group of patients 
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with schizophrenia.
Variables predicting degree of treatment adherence in the 
depression group
For the group of patients with depression, a multiple 
regression analysis with “Degree of Treatment 
Adherence” as the dependent variable and the 
scores on the BDI-II and the PSQI as predictors 
was conducted. Note that the adherent depression 
group had a mean of 13.44 days (SD = 2.02 days). 
Table 3 shows the results of the multiple regression 
analysis using the enter method for predicting 
“Degree of Treatment Adherence”. The scores on the 
BDI-II and the PSQI were insignificant predictors.
Variables predicting degree of treatment adherence in 
the schizophrenia group
For the group of patients with schizophrenia, a 
multiple regression analysis was conducted with 
“Degree of Treatment Adherence” as the dependent 
variable and the scores on the PANSS-total (also 
split into PANSS-positive, PANSS-negative, and 
PANSS-general psychopathology) and on the PSQI 
as predictors. Note that the adherent schizophrenia 
group had a mean of 12.82 days (SD = 2.43 days). 
Table 4 shows the results of the multiple regression 
analysis using the enter method for predicting 
“Degree of Treatment Adherence”. The scores on the 
PANSS-total, PANSS-positive, PANSS-negative, and 
PANSS-general psychopathology were insignificant 
predictors while the score on the PSQI was a 
significant predictor. Moreover, the score on the 
PANSS-negative and the score on the PSQI correlated 
significantly with “Degree of Treatment Adherence” 
(PANSS-negative: r = 0.31, P < 0.05; PSQI: r = 0.39, 
P < 0.05).
DISCUSSION
The general results of our study showed that for 
the group of patients with depression, in contrast 
to our hypotheses, symptom severity and quality 
of sleep did not significantly predict whether a 
patient would be adherent to treatment or not; the 
severity of depression and the quality of sleep did 
not differ significantly between treatment adherent 
and non-adherent patients. For the group of patients 
with schizophrenia, in line with our hypotheses, a 
relationship was found between symptom severity 
and treatment adherence, as well as between quality 
of sleep and treatment adherence; however, the 
directions of those relationships were contrary to 
our expectations. Experiencing more severe negative 
symptoms was found to be significantly related to 
better treatment adherence. Moreover, quality of 
sleep did serve as a significant predictor of treatment 
adherence; however, in general, the patients with 
schizophrenia who reported a worse quality of 
sleep were more treatment-adherent than those who 
reported a better quality of sleep and not vice versa.
The surprising findings that no relationships were 
found between quality of sleep and treatment 
adherence and between symptom severity and 
treatment adherence in the depression group are 
opposed to the findings by Ong et al.[2] who investigated 
the risk factors associated with dropping out of group 
cognitive-behavior therapy for insomnia and found 
that short sleep duration and elevated symptoms of 
depression at baseline could be especially associated 
with an increased risk of early therapy dropout. 
Also, in their study, Phillips et al.[23] reported that 
women with greater sleep disturbances had a higher 
level of depressive symptoms and poor adherence to 
their medication regimen. Noticeably, research that 
targets adherence to medication dominates research 
that targets adherence to treatment. Possibly, 
different risk factors may be related to these two 
forms of adherence, which might make a direct 
comparison between studies that target adherence 
to medication and studies that target adherence to 
treatment difficult. This suggestion remains to be 
verified. Overall, to date, only a few studies have 
been conducted on treatment non-adherence by 
patients with depression and its predictors,[38] so 
further research is warranted.
Nevertheless, in the group of patients with 
schizophrenia in the present study, symptom 
severity and quality of sleep may be related to better 
treatment adherence. Steger et al.[39] reported similar 
findings. The researchers assessed medication 
adherence in a sample of 216 patients with a first 
episode of psychosis; the assessments were done 
at program entry and three and six months later. 
They found an association between early resolution 
of negative symptoms and poor adherence. Patients 
whose positive symptoms had been resolved 
after three months of treatment did not show a 
change in adherence behavior compared to those 
whose symptoms persisted. On the contrary, early 
resolution of negative symptoms was significantly 
associated with less medication adherence compared 
to the patients whose negative symptoms persisted. 
Unfortunately, patients whose negative symptoms 
had been resolved but who were non-adherent 
experienced a worsening of both positive and negative 
symptoms at six month. Steger et al.[39] concluded 
that patients who experience a rapid reduction of 
negative symptoms must be closely followed, as they 
are at high risk for non-adherence. As a possible 
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explanation for these findings, the researchers stated 
that patients might associate reduction of negative 
symptoms with a return to normal functioning and, 
therefore, might decide that they no longer need 
medication. This assumption is supported by the 
finding of Quach et al.[40] whose study indicated that 
a high level of functioning after one year of treatment 
was associated with non-adherence at year two.
However, opposing findings have also been reported 
in the treatment adherence literature on patients 
with schizophrenia. A study by Tattan and Creed[41] 
regarding negative symptoms of schizophrenia and 
compliance with medication, for instance, found 
that patients with schizophrenia who had a poor 
medication compliance experienced a significantly 
greater severity of negative symptoms. Especially 
avolition, apathy, and alogia were related to poor 
compliance. The researchers presumed that patients 
who suffered from avolition and apathy would lack 
the motivation to regularly go to a satellite clinic. 
They also suggested that these patients might 
question the beneficial effects that the medication 
given at such clinics had had on their positive 
symptoms and might have instead focused on the 
limited effect that the medication had had on the 
negative symptoms from which they still suffer. 
Another point considered was that patients with 
alogia could possibly lack insight into their illness 
and, therefore, might not understand the importance 
of taking medication regularly. In sum, hitherto, as for 
depression, not much research has been conducted 
on the relationship between symptom severity and 
treatment adherence in patients with schizophrenia, 
and the results are conflicting.[39-41] Clearly, negative 
symptoms can be related to adherence, but further 
research is needed to gain a better understanding of 
this relationship.
An interesting new finding of our study is the fact 
that poor quality of sleep significantly predicted 
better treatment adherence in the group of patients 
with schizophrenia. This finding contradicts the 
finding in the study by Ong et al.[2] who reported that 
insomnia might be a risk factor for poor treatment 
adherence. To the authors’ knowledge, this study was 
among the first to investigate a possible relationship 
between quality of sleep and treatment adherence in 
patients with schizophrenia; therefore, comparing 
this group of patients to another that has sleep 
disorders such as obstructive sleep apnoea and 
insomnia might be difficult. Possibly, the patients 
with a worse subjective quality of sleep were more 
treatment adherent because they could benefit from 
completing the sleep log and, hence, register their own 
sleeping patterns for a period of two weeks. Patients 
without sleeping problems might not understand the 
therapeutic use of registering their sleeping patterns 
and, therefore, might be more likely to not complete 
the sleep log.
In sum, treatment adherence appears to be a complex 
phenomenon and can only partly be associated with 
symptom severity and quality of sleep in patients 
with schizophrenia and patients with depression. 
Some studies indicate, for instance, that a weak 
therapeutic alliance and low insight might be related 
to poor adherence in patients with schizophrenia.[42] 
Another study by Spiekermann et al.[43] stated that 
patients with schizophrenia who had stronger 
cognitive impairments showed lower adherence 
behavior compared to those without cognitive 
impairments.
The present study has several limitations that should 
be discussed in order to correctly interpret its results. 
One limitation of our study is the fact that all data 
were derived from self-report inventories, which 
have their strengths and weaknesses.[44] However, 
the disadvantages, for instance, self-report measures 
being potentially biased by social desirability,[45] might 
have negatively affected the reliability of the results. 
Moreover, future studies might vary in their means to 
measure treatment adherence. For instance, attendance 
at a psycho-education group for patients with 
schizophrenia[46] could be additionally used to measure 
treatment adherence. Another limitation of our study 
is that a mixed sample of subjects, e.g., outpatients 
with schizophrenia and outpatients with depression, 
was used. Although we have presented our treatment-
adherence results for the depression group and the 
schizophrenia group separately, having a larger sample 
of one patient group in order to investigate the possible 
relationships between symptom severity, quality of 
sleep, and treatment adherence would have been better 
because the main reasons related to non-adherence in 
patients with schizophrenia and those with depression 
may differ significantly. This is an important issue for 
future research. Finally, the exploratory nature of the 
analyses, as well as the cross-sectional study design,[47,48] 
used in the present study should be mentioned as 
further limitations, making it impossible to generalisze 
the results.
In conclusion, the current exploratory study revealed 
a significant positive relationship between symptom 
severity and treatment adherence, as well as a significant 
negative relationship between quality of sleep and 
treatment adherence in patients with schizophrenia, 
but no significant relationships between symptom 
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severity, quality of sleep, and treatment adherence 
were found in patients with depression. However, 
more research is needed to identify possible risk 
factors that can be related to treatment non-adherence 
to, in a second step, determine strategies to improve 
treatment adherence. Treatment non-adherence might 
be reduced, and at best prevented, if specific predictors 
can be related to the adherence behavior of psychiatric 
patients. Furthermore, identifying the characteristics 
of clinical patients who drop out of treatment could 
lead to improvements in the care these patients receive.
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